Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia

Michael Z. Lerner, Benjamin A. Lerner, Amit A. Patel, Andrew Blitzer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives/Hypothesis: The objective of this study was to determine the influence of gender on onabotulinum toxin A dosing for the treatment of adductor spasmodic dysphonia symptoms. Study Design: Retrospective review. Methods: A chart review of the senior author's database of botulinum toxin injections was performed. Patients diagnosed with adductor spasmodic dysphonia who received onabotulinum toxin A (BoNTA) injections to the thyroarytenoid muscle for at least 5 years were included for study. Patients who received alternate formulations of botulinum toxin (Myobloc, Dysport, or Xeomin) and patients with alternate diagnoses, such as abductor spasmodic dysphonia, tremor, and oromandibular dystonia, were excluded. The average BoNTA dose was calculated for each patient and statistical analysis was performed comparing the male and female groups. Results: A total of 201 patients (52 males and 149 females) met inclusion criteria. The average follow-up times for the male and female groups were 10.2 ± 3.6 and 11.1 ± 4 years, respectively. The average BoNTA doses for the male and female groups were 0.6 ± 0.42 U and 1.3 ± 1.1 U, respectively. Statistical analysis was performed using an independent samples two-tailed t test yielding a P value of .0000000002. A large effect size was noted with Cohen's d = 0.85. Conclusions: The data from this retrospective chart review reveal a statistically and clinically significant correlation between female gender and higher average BoNTA dose for symptom control in adductor spasmodic dysphonia. Explanations for this observation are speculative and include a possible inverse relationship between optimal BoNTA dose and vocal fold mass and possibly greater neutralizing antibody formation among female patients.

Original languageEnglish (US)
JournalLaryngoscope
DOIs
StateAccepted/In press - 2016
Externally publishedYes

Fingerprint

Dysphonia
Botulinum Toxins
Laryngeal Muscles
Injections
Dystonia
Vocal Cords
Tremor
Neutralizing Antibodies
Antibody Formation
onabotulinumtoxinA
Retrospective Studies
Databases

Keywords

  • Botox
  • Botulinum toxin
  • Dystonia
  • Gender
  • Onabotulinum toxin
  • Spasmodic dysphonia
  • Voice

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia. / Lerner, Michael Z.; Lerner, Benjamin A.; Patel, Amit A.; Blitzer, Andrew.

In: Laryngoscope, 2016.

Research output: Contribution to journalArticle

@article{76085540e1d045eca0fdfcbe2f659fad,
title = "Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia",
abstract = "Objectives/Hypothesis: The objective of this study was to determine the influence of gender on onabotulinum toxin A dosing for the treatment of adductor spasmodic dysphonia symptoms. Study Design: Retrospective review. Methods: A chart review of the senior author's database of botulinum toxin injections was performed. Patients diagnosed with adductor spasmodic dysphonia who received onabotulinum toxin A (BoNTA) injections to the thyroarytenoid muscle for at least 5 years were included for study. Patients who received alternate formulations of botulinum toxin (Myobloc, Dysport, or Xeomin) and patients with alternate diagnoses, such as abductor spasmodic dysphonia, tremor, and oromandibular dystonia, were excluded. The average BoNTA dose was calculated for each patient and statistical analysis was performed comparing the male and female groups. Results: A total of 201 patients (52 males and 149 females) met inclusion criteria. The average follow-up times for the male and female groups were 10.2 ± 3.6 and 11.1 ± 4 years, respectively. The average BoNTA doses for the male and female groups were 0.6 ± 0.42 U and 1.3 ± 1.1 U, respectively. Statistical analysis was performed using an independent samples two-tailed t test yielding a P value of .0000000002. A large effect size was noted with Cohen's d = 0.85. Conclusions: The data from this retrospective chart review reveal a statistically and clinically significant correlation between female gender and higher average BoNTA dose for symptom control in adductor spasmodic dysphonia. Explanations for this observation are speculative and include a possible inverse relationship between optimal BoNTA dose and vocal fold mass and possibly greater neutralizing antibody formation among female patients.",
keywords = "Botox, Botulinum toxin, Dystonia, Gender, Onabotulinum toxin, Spasmodic dysphonia, Voice",
author = "Lerner, {Michael Z.} and Lerner, {Benjamin A.} and Patel, {Amit A.} and Andrew Blitzer",
year = "2016",
doi = "10.1002/lary.26265",
language = "English (US)",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia

AU - Lerner, Michael Z.

AU - Lerner, Benjamin A.

AU - Patel, Amit A.

AU - Blitzer, Andrew

PY - 2016

Y1 - 2016

N2 - Objectives/Hypothesis: The objective of this study was to determine the influence of gender on onabotulinum toxin A dosing for the treatment of adductor spasmodic dysphonia symptoms. Study Design: Retrospective review. Methods: A chart review of the senior author's database of botulinum toxin injections was performed. Patients diagnosed with adductor spasmodic dysphonia who received onabotulinum toxin A (BoNTA) injections to the thyroarytenoid muscle for at least 5 years were included for study. Patients who received alternate formulations of botulinum toxin (Myobloc, Dysport, or Xeomin) and patients with alternate diagnoses, such as abductor spasmodic dysphonia, tremor, and oromandibular dystonia, were excluded. The average BoNTA dose was calculated for each patient and statistical analysis was performed comparing the male and female groups. Results: A total of 201 patients (52 males and 149 females) met inclusion criteria. The average follow-up times for the male and female groups were 10.2 ± 3.6 and 11.1 ± 4 years, respectively. The average BoNTA doses for the male and female groups were 0.6 ± 0.42 U and 1.3 ± 1.1 U, respectively. Statistical analysis was performed using an independent samples two-tailed t test yielding a P value of .0000000002. A large effect size was noted with Cohen's d = 0.85. Conclusions: The data from this retrospective chart review reveal a statistically and clinically significant correlation between female gender and higher average BoNTA dose for symptom control in adductor spasmodic dysphonia. Explanations for this observation are speculative and include a possible inverse relationship between optimal BoNTA dose and vocal fold mass and possibly greater neutralizing antibody formation among female patients.

AB - Objectives/Hypothesis: The objective of this study was to determine the influence of gender on onabotulinum toxin A dosing for the treatment of adductor spasmodic dysphonia symptoms. Study Design: Retrospective review. Methods: A chart review of the senior author's database of botulinum toxin injections was performed. Patients diagnosed with adductor spasmodic dysphonia who received onabotulinum toxin A (BoNTA) injections to the thyroarytenoid muscle for at least 5 years were included for study. Patients who received alternate formulations of botulinum toxin (Myobloc, Dysport, or Xeomin) and patients with alternate diagnoses, such as abductor spasmodic dysphonia, tremor, and oromandibular dystonia, were excluded. The average BoNTA dose was calculated for each patient and statistical analysis was performed comparing the male and female groups. Results: A total of 201 patients (52 males and 149 females) met inclusion criteria. The average follow-up times for the male and female groups were 10.2 ± 3.6 and 11.1 ± 4 years, respectively. The average BoNTA doses for the male and female groups were 0.6 ± 0.42 U and 1.3 ± 1.1 U, respectively. Statistical analysis was performed using an independent samples two-tailed t test yielding a P value of .0000000002. A large effect size was noted with Cohen's d = 0.85. Conclusions: The data from this retrospective chart review reveal a statistically and clinically significant correlation between female gender and higher average BoNTA dose for symptom control in adductor spasmodic dysphonia. Explanations for this observation are speculative and include a possible inverse relationship between optimal BoNTA dose and vocal fold mass and possibly greater neutralizing antibody formation among female patients.

KW - Botox

KW - Botulinum toxin

KW - Dystonia

KW - Gender

KW - Onabotulinum toxin

KW - Spasmodic dysphonia

KW - Voice

UR - http://www.scopus.com/inward/record.url?scp=84992561352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992561352&partnerID=8YFLogxK

U2 - 10.1002/lary.26265

DO - 10.1002/lary.26265

M3 - Article

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

ER -